Launches Arbitration Claim Against J&J
Basilea Shares Sink on Delay in EU Approval of Zevtera
Shares in Basilea Pharmaceutica AG dropped by more than 36 percent Tuesday on news that European Union (EU) approval of Zevtera (ceftobiprole), expected during the current quarter, would be delayed until at least the year end. (BioWorld International)